Anticlusterin Treatment Enhances Chemotherapy Effectiveness in Breast Cancer
Author Information
Author(s): Redondo Maximino, Téllez Teresa, Roldan Maria J, Serrano Alfonso, García-Aranda Maria, Gleave Martin E, Hortas Maria L, Morell Miguel
Primary Institution: Hospital Costa del Sol
Hypothesis
Clusterin may be a key factor in the resistance of breast cancer cells to chemotherapy, and targeting it could enhance treatment efficacy.
Conclusion
Combining anticlusterin treatment with chemotherapy drugs like paclitaxel and doxorubicin significantly increases their effectiveness against breast cancer cells.
Supporting Evidence
- Anticlusterin treatment significantly reduced cell viability compared to control treatments.
- Dexamethasone pretreatment inhibited chemotherapy-induced cytotoxicity, but anticlusterin treatment counteracted this effect.
- The combination of anticlusterin treatment with chemotherapy resulted in higher apoptosis rates in breast cancer cells.
Takeaway
This study shows that a special treatment can help cancer drugs work better by blocking a protein that helps cancer cells survive.
Methodology
Breast cancer cell lines were treated with anticlusterin oligonucleotides or antibodies alongside standard chemotherapy drugs, and cell viability was assessed.
Limitations
The study primarily focuses on in vitro results, which may not fully translate to in vivo conditions.
Statistical Information
P-Value
0.002
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website